From the Guidelines
Diagnosing cardiovascular disease (CVD) requires a comprehensive approach combining patient history, physical examination, laboratory tests, and imaging studies, with the initial evaluation including assessment of risk factors and selection of non-invasive diagnostic tests based on clinical likelihood of CAD and patient characteristics, as recommended by the 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes 1. The diagnostic approach should prioritize the assessment of risk factors, including age, family history, smoking status, hypertension, diabetes, obesity, and physical inactivity.
- The initial evaluation should include vital signs, particularly blood pressure, heart and lung examination, and assessment for peripheral edema.
- Basic laboratory tests are essential, including lipid profile, fasting blood glucose, HbA1c, complete blood count, and renal function tests.
- Specific cardiac biomarkers like troponin and BNP should be measured when acute coronary syndrome or heart failure is suspected.
- Standard diagnostic tests include electrocardiogram (ECG) to detect arrhythmias, conduction abnormalities, or evidence of ischemia or infarction.
- Advanced imaging may include echocardiography, stress testing, coronary CT angiography, or invasive coronary angiography, with the selection of the initial non-invasive diagnostic test based on clinical likelihood of CAD, patient characteristics, local expertise, and availability of tests, as recommended by the 2019 ESC guidelines on imaging in chronic coronary syndromes 1.
- Risk calculators, such as the ASCVD Risk Estimator, can help determine 10-year cardiovascular risk, and risk stratification should be based on clinical assessment and the result of the diagnostic test initially employed for making a diagnosis of CAD.
- The use of risk prediction tools, such as those reviewed in the 2020 report from the ESC Prevention of CVD Programme 1, can help identify individuals at high risk of CVD and provide personalized preventive measures.
- Dietary interventions, such as the DASH diet, can be effective in preventing CVD, and combining diet with other interventions, such as exercise and smoking cessation, can increase efficacy, as found in the 2023 systematic review of international clinical guidelines on dietary interventions for CVD prevention 1.
From the Research
Guidelines for Diagnosing Cardiovascular Disease (CVD)
The diagnosis of CVD involves a comprehensive approach, considering various risk factors and diagnostic tools. Some key points to consider are:
- The management of CVD is currently far from optimal, even in well-developed healthcare systems 2
- A thorough understanding of the multifactorial nature of CVD is essential to its effective management 2
- Recent evidence classifies atherosclerosis as a latent disease affecting all-sized arteries, with a predilection for arterial branching points of decreased or absent blood supply 3
- Modifiable and non-modifiable risk factors for CVD include age, male gender, family history, obesity, smoking, diabetes mellitus, and hypertension 3
Diagnostic Tools and Risk Assessment
Some diagnostic tools and risk assessment strategies for CVD include:
- Lipid profile testing to assess cholesterol levels and lipid metabolism 4
- Blood pressure monitoring to diagnose hypertension 5
- Assessment of other cardiovascular risk factors, such as smoking, diabetes, and obesity 5
- Use of risk assessment tools, such as the estimated 10-year CVD risk, to identify individuals at high risk of CVD 5
Management and Prevention of CVD
Some key points to consider in the management and prevention of CVD are:
- Behavioral counseling interventions can promote a healthy diet and physical activity, and have a moderate net benefit on CVD risk in adults at increased risk for CVD 5
- Management practices for CVD can differ by type of acute coronary syndrome (ACS) and discharge medication should be guided by the latest guidelines 4
- Traditional risk factors for CVD, such as hypertension and hyperlipidemia, can have a significant impact on length of stay and mortality in patients with ACS 6